A straightforward, 4-step workflow on existing qPCR platforms. No need to invest in expensive hardware, data handling, or bioinformatics.
100% specificity, with the ability to consistently generate results from poor quality samples.
No need for complex bioinformatics. Biofidelity provides fast, simple cloud-based software at no additional cost.
Aspyre Lung Reagents can provide results in hours, enabling rapid input into NSCLC research.
With simple integration into your laboratory, Aspyre Lung Reagents enable lightning-fast analysis on samples you control.
Simultaneously analyze DNA & RNA from tissue or blood, maximizing the opportunity to identify mutations and fusions, while avoiding the time and expense of running separate assays or missing fusion positive samples.
98% of results provided within 2 days vs. 10-14 days with NGS, enabling earlier treatment decisions.
25-40% of lung cancer tissue samples fail NGS. Aspyre provides actionable clinical information from samples deemed to be insufficient quantity (QNS) or failed NGS QC. Challenging samples include pleural effusions, fine needle aspirates and others.1
Aspyre is more sensitive than both NGS and single-gene PCR tests, providing a greater likelihood of detecting an actionable variant.
Can be used on either blood or tissue samples with tumor content as low as 10%. Reflex option to blood if needed.
The Aspyre Clinical Test for Lung detects somatic mutations from DNA, and gene fusions directly from RNA maximizing the opportunity to identify mutations and fusions, while avoiding the additional time and expense of running separate assays.
The Aspyre Clinical Test for Lung has demonstrated successful results in 98% of samples that failed NGS due to QC failure.2
